HBM variants that modulate bone mass and lipid levels

Abstract

The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Description

FIELD OF THE INVENTION[0001]The present invention relates generally to the field of genetics, genomics and molecular biology. The invention relates to methods and materials used to isolate, detect and sequence a high bone mass gene and corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass (HBM) gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in the ontology and physiology of bone development. The invention also provides nucleic acids, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bbne development, and methods of diagnosing and treating diseases involved in bone development and lipid levels. The invention further relates to transgenic animals for studying the HBM phenotype and related variant phenotypes, the mechanism of action of the HBM gene ...

AI Technical Summary

Problems solved by technology

Osteoporosis affects men as well as women, and, taken with other abnormalities of bone, presents an ever-increasing health risk for an aging population.

This rapid loss is generally associated with an increase of bone resorption and formation.

However, the resorptive cycle is more dominant and the result is a net loss of bone mass.

The results of osteoporosis are both personally harmful, and also account for a large economic loss due to its chronicity and the need for extensive and long-term support (hospitalization and nursing home care) from the disease sequelae.

Although this therapy frequently is successful, patient compliance is low, primarily due to the undesirable side-effects of chronic estrogen treatment.

This protocol is similar to that which is used in birth control regimens, and often is not tolerated by women because of the side-effects characteristic of progestin.

The use of calcitonin has been somewhat limited, however.

Its effects are very modest in increasing bone mineral density and the treatment is very expensive.

Senile osteoporosis is similar to postmenopausal osteoporosis in that it is marked by the loss of bone mineral density and resulting increase in fracture rate, morbidity, and associated mortality.

Treatment of this disease has not been very satisfactory.

These studies are difficult because bone mass (the phenotype) is a continuous, quantitative, polygenic trait, and is confounded by environmental factors such as nutrition, co-morbid disease, age, physical activity, and other factors.

Also, this type of study design requires large numbers of subjects.

In particular, the results of VDR studies to date have been confusing and contradictory (Garnero et al, J.

Furthermore, the work thus far has not shed much light on the mechanism(s) whereby the genetic influences might exert their effect on bone mass.

While it is well known that peak bone mass is largely determined by genetic rather than environmental factors, studies to determine the gene loci (and ultimately the genes) linked to variation in bone mass are difficult and expensive.

However, genetic linkage studies involving bone mass are hampered by two major problems.

The first problem is the phenotype, as discussed briefly above.

Bone mass is a continuous, quantitative trait, and establishing a discrete phenotype is difficult.

The second problem is the age component of the phenotype.

By the time an individual can be identified as having low bone mass, there is a high probability that their parents or other members of prior generations will be deceased and therefore unavailable for study, and younger generations may not have even reached peak bone mass, making their phenotyping uncertain for genetic analysis.

However, few markers are sufficiently polymorphic as to be informative in all those individuals.

Images